Cardiac fibrosis, a hallmark of heart failure and various cardiomyopathies, represents a complex pathological process that has long challenged therapeutic intervention. High-throughput omics ...
Bayer and Suzhou Puhe BioPharma Co.,Ltd., a clinical-stage biotechnology company, announced that they have entered into a global license agreement for Puhe BioPharma’s oral, small molecule PRMT5 ...
Bayer BAYRY announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company. Suzhou Puhe BioPharma is focused on the research and development of innovative ...
Bayer and Suzhou Puhe BioPharma Co. Ltd., a clinical-stage biotechnology company, on Wednesday announced that they have entered into a global license agreement for Puhe BioPharma's oral, small ...
Researchers have uncovered a promising therapeutic target for adenoid cystic carcinoma (ACC), a rare cancer of the salivary ...
Zacks Investment Research on MSN6d
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharmaBayer BAYRY announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company.Suzhou ...
Tango Therapeutics (TNGX), a biotechnology company with a market capitalization of $190 million, has been making waves in the oncology space with its focus on developing PRMT5 inhibitors for solid ...
Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors Chondrosarcomas are rare cancers of cartilage with limited systemic therapy options. To ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback